NASDAQ:CNMD - CONMED Stock Price, News, & Analysis

Get Started

$70.7050 +3.97 (+5.95 %)

(As of 01/23/2019 02:30 PM ET)

Previous Close$66.74

Today's Range$67.66 - $74.23

52-Week Range$55.88 - $83.49

Volume765,760 shs

Average Volume171,783 shs

Market Capitalization$1.99 billion

P/E Ratio37.41

Dividend Yield1.20%

Beta0.63

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors; and uterine manipulator (VCARE) for use in increasing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, it offers general surgery product in the areas of endoscopic technologies, including minimally invasive diagnostic and therapeutic products; critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician's office electrosurgical product used by dermatologists. The company's products are used by surgeons and physicians in orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

Receive CNMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Electromedical equipment

Sub-IndustryHealth Care Equipment

SectorMedical

Current SymbolNASDAQ:CNMD

Previous Symbol

CUSIP20741010

Webwww.conmed.com

Phone315-797-8375

Debt

Debt-to-Equity Ratio0.68

Current Ratio2.20

Quick Ratio1.27

Price-To-Earnings

Trailing P/E Ratio37.41

Forward P/E Ratio32.58

P/E Growth2.4

Sales & Book Value

Annual Sales$796.39 million

Price / Sales2.50

Cash Flow$4.2491 per share

Price / Cash Flow16.64

Book Value$22.60 per share

Price / Book3.13

Profitability

EPS (Most Recent Fiscal Year)$1.89

Net Income$55.48 million

Net Margins8.56%

Return on Equity9.51%

Return on Assets4.51%

Miscellaneous

Employees3,100

Outstanding Shares28,130,000

Market Cap$1.99 billion

OptionableOptionable

CONMED (NASDAQ:CNMD) Frequently Asked Questions

What is CONMED's stock symbol?

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED declared a quarterly dividend on Friday, November 9th. Stockholders of record on Friday, December 14th will be given a dividend of $0.20 per share on Monday, January 7th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.13%. The ex-dividend date of this dividend is Thursday, December 13th. View CONMED's Dividend History.

How were CONMED's earnings last quarter?

CONMED Co. (NASDAQ:CNMD) posted its quarterly earnings results on Tuesday, January, 22nd. The medical technology company reported $0.73 EPS for the quarter, meeting the Zacks' consensus estimate of $0.73. The medical technology company earned $242.40 million during the quarter, compared to analysts' expectations of $228.40 million. CONMED had a return on equity of 9.51% and a net margin of 8.56%. The business's quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.69 earnings per share. View CONMED's Earnings History.

When is CONMED's next earnings date?

CONMED is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for CONMED.

What guidance has CONMED issued on next quarter's earnings?

CONMED issued an update on its FY19 earnings guidance on Tuesday, January, 22nd. The company provided EPS guidance of $2.42-$2.47 for the period, compared to the Thomson Reuters consensus estimate of $2.42. The company issued revenue guidance of $902.6-$911.8 million, compared to the consensus revenue estimate of $889.37 million.CONMED also updated its FY 2019 guidance to $2.42-2.47 EPS.

What price target have analysts set for CNMD?

3 equities research analysts have issued twelve-month target prices for CONMED's shares. Their predictions range from $78.00 to $81.00. On average, they anticipate CONMED's stock price to reach $79.3333 in the next twelve months. This suggests a possible upside of 12.2% from the stock's current price. View Analyst Price Targets for CONMED.

What is the consensus analysts' recommendation for CONMED?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CONMED.

What are Wall Street analysts saying about CONMED stock?

Here are some recent quotes from research analysts about CONMED stock:

1. Needham & Company LLC analysts commented, "CNMD’s 4Q18 revenue beat consensus while its EPS was in line with consensus. Management provided 2019 revenue and EPS guidance that were both above consensus. Revenue growth improved to 10.8% CC (or ~9.3% CC after adjusting for an extra selling day) in 4Q18 from 8.1% CC in 3Q18 despite a more difficult comp. CNMD’s revenue grew 8.4% in 2018, which is ~400 bps above the mid-point of its original 4-5% guidance. We believe that the 2019 revenue guidance is similarly conservative and note that management indicated that they intend to allow any revenue upside to fall through to the bottom line rather than reinvesting this as in 2018. Given this, we reiterate our Buy rating." (1/23/2019)
2. According to Zacks Investment Research, "CONMED operates in a highly competitive environment, especially with respect to the General Surgery business. The company’s high long-term debt is a concern. Lower healthcare spending owing to foreign exchange volatility is a headwind. Moreover, CONMED’s stock looks quite overvalued at the moment. On the positive side, the company’s solid sales guidance for 2018 paints a bright picture. Strong performances in the Orthopedic and General surgery units and the company’s unique product portfolio are encouraging. Significant expansion in the gross and operating margins in the last reported quarter buoys optimism. The company has invested significantly in R&D in recent times, which reflects focus on innovation. CONMED has outperformed the industry in a year’s time." (1/21/2019)

Has CONMED been receiving favorable news coverage?

Press coverage about CNMD stock has trended negative recently, according to InfoTrie. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CONMED earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned headlines about the medical technology company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days.

Who are some of CONMED's key competitors?

Some companies that are related to CONMED include Masimo (MASI), LivaNova (LIVN), GETINGE AB/ADR (GNGBY), NxStage Medical (NXTM), Natus Medical (BABY), Viewray (VRAY), AxoGen (AXGN), Semler Scientific (SMLR), BioLife Solutions (BLFS), Cutera (CUTR), Rockwell Medical (RMTI), Electrocore (ECOR), Fonar (FONR), Zynex (ZYXI) and Edap Tms (EDAP).

Who are CONMED's key executives?

CONMED's management team includes the folowing people:

Mr. Curt R. Hartman, CEO, Pres & Director (Age 55)
Mr. Patrick J. Beyer, Pres of CONMED International (Age 53)
Mr. Stanley W. Peters III, VP & GM of U.S. Advanced Surgical (Age 44)
Mr. Nathan Folkert, VP & GM of U.S. Orthopedics (Age 44)
Mr. Todd W. Garner, Exec. VP & CFO (Age 50)

Who are CONMED's major shareholders?

CONMED's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Strs Ohio (0.26%), Bank of Montreal Can (0.26%), Louisiana State Employees Retirement System (0.03%), Diversified Trust Co (0.02%) and Meeder Asset Management Inc. (0.02%). Company insiders that own CONMED stock include Charles Farkas, Curt R Hartman, Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jo Ann Golden, Luke A Pomilio, Mark E Tryniski, Nathan Folkert, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Institutional Ownership Trends for CONMED.

Which major investors are selling CONMED stock?

CNMD stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Jo Ann Golden, Luke A Pomilio, Nathan Folkert, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Insider Buying and Selling for CONMED.

Which major investors are buying CONMED stock?

CNMD stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio, Bank of Montreal Can, Meeder Asset Management Inc. and Diversified Trust Co. Company insiders that have bought CONMED stock in the last two years include Charles Farkas, Curt R Hartman, Heather L Cohen and Mark E Tryniski. View Insider Buying and Selling for CONMED.

How do I buy shares of CONMED?

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CONMED's stock price today?

One share of CNMD stock can currently be purchased for approximately $70.7050.

How big of a company is CONMED?

CONMED has a market capitalization of $1.99 billion and generates $796.39 million in revenue each year. The medical technology company earns $55.48 million in net income (profit) each year or $1.89 on an earnings per share basis. CONMED employs 3,100 workers across the globe.

What is CONMED's official website?

The official website for CONMED is http://www.conmed.com.

How can I contact CONMED?

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.

MarketBeat Community Rating for CONMED (NASDAQ CNMD)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		311 (Vote Outperform)
Underperform Votes:		243 (Vote Underperform)
Total Votes:		554

MarketBeat's community ratings are surveys of what our community members think about CONMED and other stocks. Vote "Outperform" if you believe CNMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/23/2019 by MarketBeat.com Staff